Iowa State University

Engineers developing no-touch, mail-in, fast-scan test for COVID-19, other outbreaks

3-Aug-2020 8:00 AM EDT, by Iowa State University

Newswise — AMES, Iowa – There would be no tents set up in parking lots. No long lines of cars. No medical staff in full protective gear. No waiting for results. 

Instead, you’d take your own COVID-19 diagnostic test at home with a $1 (or so) kit. You’d take your own nasal and cough samples. You’d spread the samples on a card. You’d stuff the card in an envelope with a virus-killing coating and let everything incubate overnight. Then you’d drop the envelope at a collection center or in the mail. 

The unopened envelope would be scanned by an electronic reader to determine a positive or negative result. Then, that never-opened envelope, samples and all, would be dropped in an incinerator.

The electronic reader would automatically text or email your results. 

“We’re trying to make it so that no one has to touch the samples,” said Nigel Reuel, an assistant professor of chemical and biological engineering at Iowa State University. “Let’s see if we can make this possible.” 

Toehold switches and reporter proteins

When he thinks about a better way to do diagnostic testing, Reuel envisions a low-cost, mail-safe, fast-scan “diagnostic platform that is well-suited for widespread monitoring of infection during pandemics,” according to a summary of his project. 

Reuel has a one-year, Rapid Response Research (RAPID) grant of $200,000 from the National Science Foundation to develop the testing platform. The agency’s RAPID grants allow it to “quickly process and support research that addresses an urgent need,” according to an agency announcement. 

Reuel said his idea would address several urgent testing problems: “This approach off-loads the burden of diagnostics from health workers, eliminates the increased use of limited personal protective equipment, and provides a better response to outbreaks,” he wrote. 

Not only that, it would provide a real-time outbreak map with demographic details to help public health officials monitor the infection. 

Key to the technology is a new sensor system based on “toehold switches” that detect target RNA genetic material. That detection triggers production of “reporter” proteins that can change the color of a sensor or, in this case, the frequency of a sensor’s signal. 

During an academic conference last winter, Reuel heard more about the toehold technology from

Keith Pardee, an assistant professor with the Leslie Dan Faculty of Pharmacy at the University of Toronto, who works in partnership with Alexander Green, an assistant professor with the Biodesign Center for Molecular Design and Biomimetics at Arizona State University. They had done prior work with the Zika virus and recently demonstrated a direct, electrical interface of their toehold circuit. They’re now collaborators on Reuel’s project. 

Reuel thought the toehold technology could fit some of his ideas for a closed, contact-free diagnostic sensing system using paper-based resonant sensors. 

From skunkworks to telltale signals

Reuel started a side, “skunkworks” project in January and February exploring the idea of using the toehold technology as a way to find general disease targets, which quickly narrowed to targeting the coronavirus that causes COVID-19. Two doctoral students in chemical and biological engineering dove into the details  – Adam Carr on the wireless sensor and Jared Dopp on the synthetic biology. 

It now looks like the finished product would involve a multilayered assembly on thick paper. The top layer would hold collected nasal or cough samples, middle layers would contain the toehold switch and bottom layers a printed, coiled resonant circuit that can be scanned for telltale frequencies. 

If there’s target COVID-19 RNA in the samples, the toehold switch would allow production of proteins that degrade a coating on the circuit resulting in a positive signal. If there’s no virus RNA, there’s no protein production, no coating degradation and a negative signal. 

Reuel said the technology can be tuned to detect other diseases or even future pandemics. 

“The driving motivation of this project,” Reuel wrote, “is to provide a faster response to enable widespread screening and tracking of an expanding viral outbreak.”

 

– 30 –




Filters close

Showing results

110 of 3321
Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.

Released: 17-Sep-2020 5:50 PM EDT
AERA and OECD to Co-Host Webinar on Education Research Worldwide in a Covid and Post-Covid World
American Educational Research Association (AERA)

The American Educational Research Association (AERA) and the Organisation for Economic Co-operation and Development (OECD) will co-host a webinar on “Education Research Worldwide in a Covid and Post-Covid World” at 9:30-11:00 am EDT Wednesday, September 23.

Newswise: 243232_web.jpg
Released: 17-Sep-2020 4:20 PM EDT
Study shows first proof that a safer UV light effectively kills virus causing COVID-19
Hiroshima University

A study conducted by Hiroshima University researchers found that using Ultraviolet C light with a wavelength of 222 nanometers which is safer to use around humans effectively kills SARS-CoV-2 -- the first research in the world to prove its efficacy against the virus that causes COVID-19.

Newswise:Video Embedded american-academy-of-dermatology-honors-detroit-physician-iltefat-h-hamzavi-with-national-patient-care-hero-award
VIDEO
Released: 17-Sep-2020 4:00 PM EDT
American Academy of Dermatology honors Detroit physician Iltefat H. Hamzavi with national “Patient Care Hero” award
American Academy of Dermatology

The American Academy of Dermatology has named board-certified dermatologist Iltefat H. Hamzavi, MD, FAAD, a Patient Care Hero for his innovative use of light therapy to sanitize masks needed by frontline health care workers.

access_time Embargo lifts in 2 days
Embargo will expire: 22-Sep-2020 11:00 AM EDT Released to reporters: 17-Sep-2020 3:20 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 22-Sep-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 17-Sep-2020 3:05 PM EDT
New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test
Mount Sinai Health System

The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood


Showing results

110 of 3321

close
1.1223